Our view, stated clearly.
We use D-chiro-inositol as a precise complementary form. At 25 mg beside 1,000 mg myo-inositol, it gives the formula a defined second signaling role while preserving the MI-led 40:1 architecture supported by comparative research.
How is D-chiro-inositol different?
D-chiro-inositol is produced from myo-inositol through an insulin-dependent epimerase. The two stereoisomers contribute to different inositol phosphoglycan second messengers, and their relative abundance varies across tissues.1
That biology argues against treating them as interchangeable. A formula high in DCI is not simply a “stronger” version of a myo-inositol formula.
What does the clinical evidence show?
Comparative human studies in women with PCOS have reported improvements with both myo-inositol and D-chiro-inositol across selected metabolic or endocrine outcomes. Some studies suggest different patterns of response between the two forms.2
This human evidence supports DCI as a relevant complementary ingredient. The 2023 international guideline does not identify one specific inositol form, dose, or combination for universal use, so population, amount, and formula context remain important.
Why keep DCI lower than myo-inositol?
A 2019 study directly compared seven MI/DCI ratios in 56 participants and reported the strongest reproductive-outcome signal with 40:1.4
We use that comparative result as a practical formulation signal: 25 mg DCI complements 1,000 mg MI while keeping the predominant myo-inositol form at the center of the formula. The study included eight participants per ratio group, so its findings remain specific to the design and outcomes studied.
DCI earns its place through distinct insulin-linked biology, comparative human research, and a transparent 25 mg amount within an MI-led 40:1 formula. Its value comes from the relationship between the two named forms.
What a responsible formula should disclose
Exact form
“Inositol,” myo-inositol, and D-chiro-inositol are not equally precise label descriptions.
Daily amount
Read the full serving—not a single capsule—and do not confuse a ratio with a dose.
Formula purpose
Each form should have a defined role rather than being added for a front-label claim.
Evidence boundary
PCOS, fertility, and metabolic conditions require individualized medical care.
D-Chiro-Inositol FAQs
Is DCI stronger than myo-inositol?+
That framing is misleading. They have related but distinct roles; one is not simply a stronger version of the other.
Why not use DCI alone?+
Some DCI-only studies exist, but ovarian physiology and ratio studies provide a rationale for retaining myo-inositol as the dominant form in a combined women's formula.
Does 25 mg have meaning without the MI amount?+
No. DCI amount and MI amount must be read together. In ESTHELIV's formula, 25 mg DCI is paired with 1,000 mg MI.
Who should ask a clinician first?+
Anyone pregnant, breastfeeding, using glucose-lowering medication, undergoing fertility care, or managing a diagnosed endocrine condition should seek individualized guidance.
References
- 2023 International Evidence-based Guideline for PCOSTeede HJ, et al. Human Reproduction. 2023;38(9):1655–1679.
- Inositol for PCOS: systematic review informing the 2023 guidelineFitz V, et al. Journal of Clinical Endocrinology & Metabolism. 2024;109(6):1630–1655.
- Myo-inositol vs D-chiro-inositol in PCOS treatmentFormuso C, et al. Minerva Ginecologica. 2015;67(4):321–325.
- Comparison of myo-inositol and D-chiro-inositol on ovarian and metabolic factorsPizzo A, et al. Gynecological Endocrinology. 2014;30(3):205–208.
- Comparison of seven MI/DCI ratiosNordio M, et al. European Review for Medical and Pharmacological Sciences. 2019;23(12):5512–5521.